Shattuck Labs (STTK) Fundamentals 2026 — Revenue Analysis | SniperIQ
Shattuck Labs (STTK) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Shattuck Labs (STTK) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Shattuck Labs (STTK) has a market capitalization of approximately
Shattuck Labs's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Shattuck Labs runs a net profit margin of -4987.4%, a gross margin of -843.8%, and an operating margin of -5266.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Shattuck Labs reported revenue of
Shattuck Labs does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Shattuck Labs carries a debt-to-equity ratio of 0.03x and a current ratio of 22.06x, with a market beta of 1.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shattuck Labs (STTK) the key facts are: market cap
Get Shattuck Labs's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.